Rheumatology 2000; 39: 844-849
© 2000 British Society for Rheumatology
Class II MHC antigens in early rheumatoid arthritis in Bath (UK) and Madrid (Spain)
1 Rheumatology and Immunology Units, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Spain,
2 The Bath Early Synovitis Group, Bath Institute for Rheumatic Diseases, RNHRD and Department of Pharmacy & Pharmacology, University of Bath, Bath, UK and
3 Centro de Transfusión de la Comunidad de Madrid, Spain
Objective. A number of studies have indicated that rheumatoid arthritis (RA) is a less severe disease in Mediterranean countries than in Northern Europe. We investigated whether differences in the frequency of class II MHC antigens might contribute to this variation in disease severity.
Methods. Typing at HLA-DR and -DQ loci was carried out at low and high resolutions by polymerase chain reaction amplification in patients with early RA of less than 6 months' duration (68 patients in Madrid and 68 in Bath) and in control subjects (929 in Madrid and 226 in Bath). Only ethnic Spanish and British individuals were included as patients and controls.
Results. Shared epitope (SE) alleles represented 19.8 and 28.9% of the total number of class II MHC alleles in controls from Madrid and Bath respectively (P = 0.00001), this difference being largely due to increased numbers of DRB1*0401 individuals in the British subjects (P = 0.0000001). Analysis of the patients showed the expected increase in SE alleles when compared with their respective control groups (Madrid, 31.6 vs 19.8%; Bath, 42.6 vs 28.9%). In Bath the SE was mainly encoded by HLA-DR4 alleles (74.1%), while in Madrid it was encoded almost equally by DR4 (51.1%) and DR1 (44.7%) alleles. The risk of developing RA in carriers of SE alleles was similar in the two cities (Bath, odds ratio 1.83, 95% confidence interval 1.23–2.78; Madrid, odds ratio 1.87, 95% confidence interval 1.25–2.77), and was largely accounted for by HLA-DRB1*0401 alleles.
Conclusion. We conclude that rheumatoid patients in Bath differ from their Spanish counterparts in class II antigen expression and allele frequency. This may be explained partly by genetic differences between the control populations in the two centres, and may help to explain the greater incidence of more severe rheumatoid disease expression seen in RA patients in the UK.
KEY WORDS: Rheumatoid arthritis, Early, Class II MHC, UK, Spain.
Correspondence to: Dr A. Balsa, Rheumatology Unit, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Carbonell, T. Cobo, A. Balsa, M. A. Descalzo, L. Carmona, and SERAP Study Group The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry Rheumatology, July 1, 2008; 47(7): 1088 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Carmona, I Gonzalez-Alvaro, A Balsa, M A. Belmonte, X Tena, R Sanmarti, and EMECAR Study Group Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity Ann Rheum Dis, September 1, 2003; 62(9): 897 - 900. [Abstract] [Full Text] [PDF]
|
|